TECNOTREE
10.6.2022 13:47:07 CEST | Business Wire | Press release
Tecnotree, a Finland-based global provider of digital transformation solutions for Digital Service Providers (DSPs), today announced that it has been selected as ‘MongoDB Independent Software Vendor (ISV) Partner of the Year - Telco’ winner in the annual MongoDB World event at New York.
Padma Ravichander, CEO Tecnotree, said “We are proud to receive this award from MongoDB for helping our customers transition to new technologies and build digital ecosystems. Our technology platform allows customers to quickly deploy new services in response to market demand. Tecnotree’s digital BSS suite 5 provides end-to-end digital transformation for our enterprise customers, creating new efficiencies along the value chains. We are honoured to have this partnership with MongoDB. As we prepare for another exciting year ahead, we will continue to work closely with them to build custom-tailored solutions for our consumers.”
‘The MongoDB Partner of the Year Awards’ honour projects and people that thrive to help MongoDB telecom customers with their journey to the cloud. They celebrate the ground-breaking use of data to build compelling applications, modernize legacy ones, and the creativity of professionals expanding the limits of technology with MongoDB. This year partners were selected based on MongoDB end customer impact and influence.
Tecnotree was selected based on its unique set of offerings in the form of Cloud management, mobility and IoT, enterprise application development, software maintenance, and real-time offerings for enhanced customer experience, with their complete range of BSS Suite products and services. Tecnotree is addressing its goals towards building digital ecosystems by providing enterprises with a variety of solutions that help them with their digital transformation journey, using MongoDB as the underlying technology.
“At MongoDB, our partners are critical to our ability to care for our customers. The last two years have been a remarkably challenging time, with widespread changes affecting the entire world—and certainly the IT industry—like never before. However, this time has also brought customers and partners together to solve common problems,” said Alan Chhabra, Executive Vice President of Worldwide Partners, MongoDB. “At MongoDB, we’re committed to helping our customers evolve to this next stage of necessary innovation and are so grateful to all our partners who help make it happen. We’re cheering on this year's winners to carry on this competition’s legacy of honouring game-changing ideas, and I look forward to seeing the influence they make on the industry and the future.”
About Tecnotree
Tecnotree is the full-stack digital business management solution provider for digital service providers, with over 40 years of deep domain knowledge, proven delivery, and transformation capability across the globe. Our open-source technology-based agile products comprise the full range (order-to-cash) of business process and subscription management for telecom and DSPs with a pre-integrated B2B2X partner ecosystem across gaming, health, education, OTT, etc. Tecnotree products, platforms, and partners support emerging ecosystems of over 1 Billion subscribers across 70+ countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220610005241/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom